Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?

about

Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement.

P2860

Q50791653-54A140C1-3F7E-4934-99EF-EDE5842F6A97

P2860

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?

Item

http://www.wikidata.org/entity/Q36331126

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Rivaroxaban and apixaban in or ...... ons and anticoagulant effects?

@ast

Rivaroxaban and apixaban in or ...... ons and anticoagulant effects?

@en

type

Item

label

Rivaroxaban and apixaban in or ...... ons and anticoagulant effects?

@ast

Rivaroxaban and apixaban in or ...... ons and anticoagulant effects?

@en

prefLabel

Rivaroxaban and apixaban in or ...... ons and anticoagulant effects?

@ast

Rivaroxaban and apixaban in or ...... ons and anticoagulant effects?

@en

P1476

Rivaroxaban and apixaban in or ...... ons and anticoagulant effects?

@en

P2093

François Sztark

http://www.w3.org/2001/XMLSchema#string

Geneviève Freyburger

http://www.w3.org/2001/XMLSchema#string

Gérard Macouillard

http://www.w3.org/2001/XMLSchema#string

Karim Khennoufa

http://www.w3.org/2001/XMLSchema#string

Sylvie Labrouche

http://www.w3.org/2001/XMLSchema#string

P2860

Measurement of rivaroxaban and apixaban in serum samples of patients.

Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.

The laboratory and the direct oral anticoagulants.

Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring?

P304

925-933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MBC.0000000000000371

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mathieu Molimard

P577

2015-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26258673

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

4664024

http://www.w3.org/2001/XMLSchema#string

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?

about

P2860

P2860

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932